Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy Evaluation of Umbilical Cord Blood-derived Mononuclear Cells in the Treatment of Refractory Neonatal Diseases

NCT06427642 is registered in ClinicalTrials.gov with Shandong Qilu Stem Cells Engineering Co., Ltd. as lead sponsor.

NCT NCT06427642
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06427642 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy Evaluation of Umbilical Cord Blood-derived Mononuclear Cells in the Treatment of Refractory Neonatal Diseases
Lead sponsor
Shandong Qilu Stem Cells Engineering Co., Ltd.
Phase
Not applicable
Overall status
Unknown status
Start date
April 1, 2022
Completion date
April 30, 2025
Enrollment
120 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bronchopulmonary dysplasia, hypoxic-ischemic encephalopathy, short bowel syndrome